Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

Mónica Alejandra Anaya-Segura; Froylan Arturo García-Martínez; Luis Ángel Montes-Almanza; Benjamín Gómez Díaz; Guillermina Ávila-Ramírez; Ikuri Alvarez-Maya; Ramón Mauricio Coral-Vázquez; Paul Mondragón-Terán; Rosa Elena Escobar-Cedillo; Noemí García-Calderón; Norma Alejandra Vázquez-Cardenas; Silvia García; Luz Berenice López-Hernández

doi:10.3390/molecules200611154

Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

Mónica Alejandra Anaya-Segura, Froylan Arturo García-Martínez, Luis Ángel Montes-Almanza, Benjamín Gómez Díaz, Guillermina Ávila-Ramírez, Ikuri Alvarez-Maya, Ramón Mauricio Coral-Vázquez, Paul Mondragón-Terán, Rosa Elena Escobar-Cedillo, Noemí García-Calderón, Norma Alejandra Vázquez-Cardenas, Silvia García, Luz Berenice López-Hernández

Escuela Superior de Medicina (ESM)

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection.

Original language	English
Pages (from-to)	11154-11172
Number of pages	19
Journal	Molecules
Volume	20
Issue number	6
DOIs	https://doi.org/10.3390/molecules200611154
State	Published - 1 Jun 2015

Keywords

Biomarkers
Duchenne
FSTN
GDF-8
MMP-2
MMP-9
Monitoring
TIMP-1

Access to Document

10.3390/molecules200611154

Cite this

Anaya-Segura, M. A., García-Martínez, F. A., Montes-Almanza, L. Á., Díaz, B. G., Ávila-Ramírez, G., Alvarez-Maya, I., Coral-Vázquez, R. M., Mondragón-Terán, P., Escobar-Cedillo, R. E., García-Calderón, N., Vázquez-Cardenas, N. A., García, S., & López-Hernández, L. B. (2015). Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules, 20(6), 11154-11172. https://doi.org/10.3390/molecules200611154

@article{fa285f59782f4105b7254419edb95095,

title = "Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection",

abstract = "Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid na{\"i}ve patients and healthy controls of similar age and also for carrier detection.",

keywords = "Biomarkers, Duchenne, FSTN, GDF-8, MMP-2, MMP-9, Monitoring, TIMP-1",

author = "Anaya-Segura, {M{\'o}nica Alejandra} and Garc{\'i}a-Mart{\'i}nez, {Froylan Arturo} and Montes-Almanza, {Luis {\'A}ngel} and D{\'i}az, {Benjam{\'i}n G{\'o}mez} and Guillermina {\'A}vila-Ram{\'i}rez and Ikuri Alvarez-Maya and Coral-V{\'a}zquez, {Ram{\'o}n Mauricio} and Paul Mondrag{\'o}n-Ter{\'a}n and Escobar-Cedillo, {Rosa Elena} and Noem{\'i} Garc{\'i}a-Calder{\'o}n and V{\'a}zquez-Cardenas, {Norma Alejandra} and Silvia Garc{\'i}a and L{\'o}pez-Hern{\'a}ndez, {Luz Berenice}",

note = "Publisher Copyright: {\textcopyright} 2015 by the authors.",

year = "2015",

month = jun,

day = "1",

doi = "10.3390/molecules200611154",

language = "Ingl{\'e}s",

volume = "20",

pages = "11154--11172",

journal = "Molecules",

issn = "1420-3049",

number = "6",

}

Anaya-Segura, MA, García-Martínez, FA, Montes-Almanza, LÁ, Díaz, BG, Ávila-Ramírez, G, Alvarez-Maya, I, Coral-Vázquez, RM, Mondragón-Terán, P, Escobar-Cedillo, RE, García-Calderón, N, Vázquez-Cardenas, NA, García, S & López-Hernández, LB 2015, 'Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection', Molecules, vol. 20, no. 6, pp. 11154-11172. https://doi.org/10.3390/molecules200611154

TY - JOUR

T1 - Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

AU - Anaya-Segura, Mónica Alejandra

AU - García-Martínez, Froylan Arturo

AU - Montes-Almanza, Luis Ángel

AU - Díaz, Benjamín Gómez

AU - Ávila-Ramírez, Guillermina

AU - Alvarez-Maya, Ikuri

AU - Coral-Vázquez, Ramón Mauricio

AU - Mondragón-Terán, Paul

AU - Escobar-Cedillo, Rosa Elena

AU - García-Calderón, Noemí

AU - Vázquez-Cardenas, Norma Alejandra

AU - García, Silvia

AU - López-Hernández, Luz Berenice

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection.

AB - Non-invasive biological indicators of the absence/presence or progress of the disease that could be used to support diagnosis and to evaluate the effectiveness of treatment are of utmost importance in Duchenne Muscular Dystrophy (DMD). This neuromuscular disorder affects male children, causing weakness and disability, whereas female relatives are at risk of being carriers of the disease. A biomarker with both high sensitivity and specificity for accurate prediction is preferred. Until now creatine kinase (CK) levels have been used for DMD diagnosis but these fail to assess disease progression. Herein we examined the potential applicability of serum levels of matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid naïve patients and healthy controls of similar age and also for carrier detection.

KW - Biomarkers

KW - Duchenne

KW - FSTN

KW - GDF-8

KW - MMP-2

KW - MMP-9

KW - Monitoring

KW - TIMP-1

UR - http://www.scopus.com/inward/record.url?scp=84938369872&partnerID=8YFLogxK

U2 - 10.3390/molecules200611154

DO - 10.3390/molecules200611154

M3 - Artículo

C2 - 26091074

SN - 1420-3049

VL - 20

SP - 11154

EP - 11172

JO - Molecules

JF - Molecules

IS - 6

ER -

Non-Invasive biomarkers for duchenne muscular dystrophy and carrier detection

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this